SM 16

SM 16 is a ALK5/ALK4 kinase inhibitor with Kis of 10 and 1.5 nM, respectively.

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ALK

Research Areas >> Inflammation/Immunology

Research Areas >> Cancer

Research Areas >> Cardiovascular Disease

ALK5[1]

[1]. Suzuki E, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 Mar 1;67(5):2351-9.

[2]. Fu K, et al. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):665-71.

[3]. Engebretsen KV, et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J Mol Cell Cardiol. 2014 Nov;76:148-57.

Brigatinib | lorlatinib | Alectinib (CH5424802) | Entrectinib | TAE684(NVP-TAE684) | AZD-3463 | Repotrectinib | Ensartinib | AP26113 | K 02288 | ASP3026 | CEP-37440 | GSK1838705A | Belizatinib